Trial Profile
A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Scleroderma
- Focus Biomarker; Therapeutic Use
- 11 Apr 2015 New trial record